Paragon 28 Inc (FNA)
10.01
+0.31
(+3.20%)
USD |
NYSE |
Nov 15, 16:00
10.00
0.00 (0.00%)
After-Hours: 20:00
Paragon 28 Research and Development Expense (TTM): 28.43M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 28.43M |
| June 30, 2024 | 30.01M |
| March 31, 2024 | 30.61M |
| December 31, 2023 | 30.08M |
| September 30, 2023 | 28.53M |
| June 30, 2023 | 27.62M |
| March 31, 2023 | 25.93M |
| Date | Value |
|---|---|
| December 31, 2022 | 24.65M |
| September 30, 2022 | 22.97M |
| June 30, 2022 | 20.76M |
| March 31, 2022 | 18.35M |
| December 31, 2021 | 16.13M |
| September 30, 2021 | 14.25M |
| June 30, 2021 | 12.48M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.48M
Minimum
Jun 2021
30.61M
Maximum
Mar 2024
23.63M
Average
25.29M
Median
Research and Development Expense (TTM) Benchmarks
| Outset Medical Inc | 43.04M |
| Perspective Therapeutics Inc | 28.53M |
| Retractable Technologies Inc | 0.654M |
| Xtant Medical Holdings Inc | 2.145M |
| Catheter Precision Inc | 0.219M |